Editors note: This is the first installment in a three-part series exploring the debate over Lyme disease diagnosis and treatment, and how it has affected Rhode Island and those with the disease locally.
North Kingstown resident Joe Russo used to be a healthy, active man.
Along with providing for himself through full-time employment, Russo was an avid hunter, always searching for game during his downtime. He also rode bicycles up and down his neighborhood.
Then, more than a decade ago, things began to change. He continued his normal daily routine but had weird symptoms that would come and go, or just didnt feel right. He would seek medical treatment to find out what was wrong, but the doctors only said he was either anxious, depressed or had allergies.
So, you try all the things they tell you and you keep trucking, he said.
The symptoms would subside, he added, but months later he would experience these other flares and weird stuff, like vertigo, dizzy spells or sweats.
As the years passed, Russo did not get better. He sought testing for everything under the sun cancer and heart issues, among others to get an answer for why his condition was deteriorating. However, the doctors at the time failed to test for another possibility Lyme disease.
Russo ultimately saw another doctor and received a confirmed diagnosis of the tick-borne disease. Relieved at finally having an answer, he went back to his primary care physician to plan a course of action.
But the response he got was unexpected.
When I went back to [my physician] with the positive lab [results], telling her, OK, we have an answer, she dismissed me, he said. Our relationship was very good. She was always caring. She tested me for everything, but once she found out I had Lyme, she wanted nothing to do with me.
Russo said he inquired in writing to seek an explanation for the dismissal, but received no response.
She left me with no reason, he said.
He added, That was humbling and it actually hurt. A doctor can dismiss you with this and theres nothing you can do about it.
***
Lyme disease is an extremely complex illness with no known cure. It can produce an array of symptoms, such as fatigue, joint pain, arthritis, muscle aches, palsy, tingling and twitching muscles and other neurological symptoms. The most common symptom is a rash, often in a bulls-eye pattern.
Dr. Jim Gloor, a North Kingstown-based physician who has specialized in Lyme disease treatment for more than three decades, said Lyme-causing bacteria is one of the most complex eukaryotic cells. Typically, he said, a persons immune system is supposed to sort out what is foreign and what is not inside a persons body. But Lyme-causing bacteria is so effective in evading the immune system that it overheats the immune engine, causing a sufferers health to go haywire.
Its like when you race an old Chevy down the highway at 100 mph over a bumpy road, somethings going to break, he said. The immune system goes haywire and we have fallout from it that ends up being other conditions that are autoimmune, which is a nice way of saying, We dont know exactly why the immune system went sour.
Gloor said the medical community has yet to fully understand the immune system and autoimmunity. Because of that, he said, a lot more research needs to be done, particularly because Lyme disease is so sophisticated.
It confuses and confounds the immune system, and it confounds the body in general, he said.
The complexity has caused confusion over how Lyme disease is diagnosed, and led to intense debate locally and nationally about treatments and whether the disease can be designated as chronic.
Dr. Utpala Bandy, a state epidemiologist and medical director for the Rhode Island Department of Healths Division of Preparedness, Infectious Disease and Emergency Medical Services, said July 26 while the state does not develop, produce, approve or endorse any guidelines on treating Lyme disease, two main sets of guidelines are in place nationally for physicians to follow.
One comes from the Infectious Diseases Society of America, or IDSA, in conjunction with the Centers for Disease Control and Prevention, and the other from the International Lyme and Associated Diseases Society, or ILADS.
The organizations have conflicting views of Lyme disease treatment and diagnoses of long-term Lyme disease.
According to the state Department of Healths Jan. 31, 2016, report on Lyme disease, the IDSA/CDC guidelines indicate patients should take the antibiotic doxycycline for several Lyme disease symptoms, including the bulls-eye rash, palsy, cardiac disease, arthritis without neurological involvement and recurrent arthritis after a single course of antibiotics.
IDSA, according to its 2006 report Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines, also maintains there is no convincing evidence for the existence of a chronic borrelia burgdorferi infection the bacteria that causes Lyme disease in patients who have received the recommended treatments. The report states antibiotic therapy is not recommended for patients with chronic Lyme disease lasting longer than six months.
In June, CDC published in its Morbidity and Mortality Weekly Report an article that also warns of serious risks for Lyme patients receiving antibiotic and intravenous treatment, even resulting in serious harm, including death.
The introduction to the article, titled Serious Bacterial Infections Acquired During Treatment of Patients Given a Diagnosis of Chronic Lyme Disease United States, reads: The term chronic Lyme disease is used by some health care providers as a diagnosis for various constitutional, musculoskeletal, and neuropsychiatric symptoms. Patients with a diagnosis of chronic Lyme disease have been provided a wide range of medications as treatment, including long courses of intravenous (IV) antibiotics. Studies have not shown that such treatments lead to substantial long-term improvement for patients, and they can be harmful. This report describes cases of septic shock, osteomyelitis, Clostridium difficile colitis, and paraspinal abscess resulting from treatments for chronic Lyme disease. Patients, clinicians, and public health practitioners should be aware that treatments for chronic Lyme disease can carry serious risks.
Other treatments, including IV infusions of hydrogen peroxide, immunoglobulin therapy, hyperbaric oxygen therapy, electromagnetic frequency treatments, garlic supplements, colloidal silver, and stem cell transplants, are also presented as being risky and not shown to produce favorable results.
The article further states, At least five randomized, placebo-controlled studies have shown that prolonged courses of IV antibiotics in particular do not substantially improve long-term outcome for patients with a diagnosis of chronic Lyme disease and can result in serious harm, including death. Five specific cases are cited to support the articles assertions.
In contrast, ILADS states on its website that it is impossible to state a meaningful success rate for the prevention of Lyme disease by a single 200 mg dose of doxycycline, and advises clinicians should not use a single doxycycline dose for treatment due to very-low quality evidence.
An optimal treatment regimen has not yet been determined, ILADS states, adding that it is too early to standardize restrictive protocols. ILADS recommends patient goals and values regarding treatment options be identified and strongly considered during a shared decision-making process.
ILADS President Dr. Samuel Shor pushed back against the CDCs June 16 report in a June 23 post on the National Center for Biotechnology Informations website. He notes one National Institutes of Health-supported study, in which 37 patients suspected of having active neuroborrelliosis a central nervous system disorder caused by Lyme disease received 10 weeks of IV Ceftriaxone, or two grams a day of the antibiotic. Pain and physical functioning improved at 12 [weeks] and was sustained at 24 weeks, Shor states.
Shor also points to another NIH-supported study in which 55 patients who felt they had an active infection of the main Lyme disease bacteria and experienced severe fatigue for longer than six months received 28 days of IV Ceftriaxone. According to Shor, a significant improvement in fatigue was sustained at 6 months.
While there are conflicting viewpoints regarding how Lyme disease should be approached and treated, one local advocate believes the state sides with the IDSA/CDC guidelines which, he believes, are outdated.
***
Lane Poor, a North Kingstown resident, was first diagnosed with Lyme disease in 1983 and still feels the effects of the disease. He has traveled around the state for years making residents aware of the disease and its harmful effects especially if it goes undetected.
In an interview in June, he said he believes the state cant accept the fact that Lyme disease is a major problem in Rhode Island, mainly because it is complicated, messy and there is no silver bullet in terms of treatment. He said the disease can result in multiple infections following the initial infection from a tick bite, and doctors are not used to it being multiple infections.
Theyre used to it as, Its one disease and you have that one thing that will kill the one disease. That doesnt happen with Lyme, he said. Lyme disease, you can get other infections. It is so hard for doctors to identify whats going on because youve got three, four different infections. Its a compound disease, and were not used to treating compound diseases.
Poor also believes there are many more Lyme disease cases in Rhode Island than the Department of Health has reported. In 2014, Rhode Island, at 86 cases per 100,000 people, had the fourth-highest Lyme disease rate in the U.S. Bandy said the department processes approximately 3,000 test reports for surveillance every summer, and of that amount, approximately 900 new Lyme disease cases are determined annually.
Poor, though, thinks Rhode Islands rate may be 10 times higher than the official figure.
Massachusetts has got an infection rate of about 800 people per 100,000, and RIDOH says we have 80, he said. Were neighbors with Massachusetts.
Both Poor and Gloor are critical of the CDCs recommended two-tier testing regimen. CDC suggests doctors first order a test known as an enzyme-linked immunosorbent assay, or ELISA, to screen for Lyme disease and then confirm it with a western blot, a procedure used to detect specific proteins.
However, according to the advocacy group LymeDisease.org, a 2002 study by Massachusetts Dr. Samuel Donta revealed 52 percent of patients with chronic Lyme disease are considered negative by the ELISA test, but the western blot shows a positive result. The College of American Pathologists, according to a 1997 study, found that ELISA tests do not have adequate sensitivity to be used for screening purposes.
Gloor said in about half of his cases, the tests are negative across the board.
LymeDisease.org states a quality test can help a doctor assess the diseases severity, estimate a patients prognosis, monitor the diseases progression, detect relapses or adjust therapies.
Unfortunately, a test with this capability does not exist for Lyme disease, according to LymeDisease.org.
Donta also said the tests are indirect and do not indicate whether or not the Lyme disease bacteria is still present. Until a proven test is developed, he said, clinical judgment and observations ... should be how one proceeds to treat such patients.
Bandy said physicians and patients can do whatever they want as long as it is a shared decision-making process.
But Lyme disease specialists in Rhode Island and beyond have had their methods questioned by health officials.
***
Over more than five years, Gloor was called to appear before the Department of Healths Board of Medical Licensure and Discipline multiple times to answer allegations from several complainants regarding his regimens for treating long-term Lyme disease, mostly with antibiotics and intravenous medicines.
The complaints, according to a 2014 consent decree filed with the health department, which was obtained by The Independent, were received by the board in 2012 and 2013, and the panel questioned the reasonableness of the diagnosis and treatment plans.
While the board found no wrongdoing regarding Gloors regimens in 2014, the decree indicates he was penalized for failing to properly document diagnoses in the assessment and plan sections of certain medical charts and with respect to the legibility of patient records. He was ordered to pay a $1,935 administrative fee to the health department and was placed on a monitoring period for one year.
In December 2016, Gloor was again cited by the Board of Medical Licensure and Discipline for poor record keeping, according to a second consent decree filed with the health department, which also indicated Gloors handwriting was barely legible and his script was so large there is only room for the barest information.
Gloor agreed to a reprimand and paid an administrative fee of $500. He additionally agreed to complete eight hours of continuing education regarding record keeping, health department spokeswoman Annemarie Beardsworth said in an email July 24.
Poor was sharply critical of the health departments dealings with Gloor, and indicated other local physicians had been treated similarly. He said the consent decrees amount to health officials serving as judge, jury and executioner all in one thing.
Doctors are scared stiff theyre going to be brought before the board for treating Lyme disease, so they dont [treat it], he added. A lot of doctors have refused to have anything to do with it.
Gloor said the issues with the health department have taken a toll emotionally and mentally, and have had a significant negative impact on his practice. He was forced to move from his former office at Wickford Junction to a new space on Post Road.
This tied me up for years, he said. My practice went to hell.
Go here to read the rest:
Behind the Lyme disease debate: 'No silver bullet' for confounding ailment - The Independent
- BIORESTORATIVE THERAPIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K) - Marketscreener.com - March 29th, 2023
- Induced Pluripotent Stem Cell for the Study and Treatment of ... - Hindawi - December 3rd, 2022
- What Happens When Everyone Realises We Can Live Much Longer? We May Find Out As Soon As 2025 - Forbes - December 3rd, 2022
- INTERNATIONAL STEM CELL CORP Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - Marketscreener.com - November 17th, 2022
- 3D Cell Culture Market stands at revenue of US$ 1.15 Bn in 2022, and is predicted to surge at a CAGR of 9.8% to hit worth of US$ 2.67 Bn during... - November 17th, 2022
- YUBO INTERNATIONAL BIOTECH LTD Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - Marketscreener.com - November 17th, 2022
- ACTINIUM PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION (form 10-Q) - Marketscreener.com - November 17th, 2022
- Top 10 Best Stem Cell Supplement Brands - Healthtrends - June 26th, 2022
- How Does Stem Cell Therapy Work and What Are the Risks? | ISCRM - June 26th, 2022
- Stem Cell Wellness Kit - June 26th, 2022
- Kangstem Biotech withdraws trial application for stem cell-based osteoarthritis treatment - KBR - June 26th, 2022
- Global Human Embryonic Stem Cell Market to be Driven by the Rapid Technological Advancements in the Forecast Period of 2022-2027 Designer Women -... - June 26th, 2022
- Sana Biotechnology Announces Multiple Preclinical Data Presentations to Showcase Its Hypoimmune Platform, Including in Type 1 Diabetes, at the... - June 26th, 2022
- Efficient terminal erythroid differentiation requires the APC/C cofactor Cdh1 to limit replicative stress in erythroblasts | Scientific Reports -... - June 26th, 2022
- Propanc Biopharma's CSO Hails Dostarlimab's Impressive Results Whilst Acknowledging More Work to Be Done in the Fight Against Cancer - Business Wire - June 26th, 2022
- Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including... - June 26th, 2022
- 10 Years of Immunotherapy: Advances, Innovations, and Better Patient Outcomes - Targeted Oncology - June 26th, 2022
- Embryonic Stem Cell Research: An Ethical Dilemma - January 30th, 2022
- Skeletal Muscle Cell Induction from Pluripotent Stem Cells - January 30th, 2022
- mRNA COVID-19 Vaccine Effectiveness in the Immunocompromised - Medscape - January 30th, 2022
- MaaT Pharma Announces Positive Interim Engraftment Data for Oral Formulation MaaT033 Allowing Early Termination of Phase 1b CIMON Study - Business... - January 30th, 2022
- European Commission Approves Merck's KEYTRUDA (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following... - January 30th, 2022
- Targeted Therapy Innovator Foresees New Paradigms in Breast Cancer - OncLive - January 30th, 2022
- Global Circulating Tumor Cells (CTC) Market Growing Demand, Future Trends, Competitive Regions and Forecast 2021 to 2027 The Oxford Spokesman - The... - January 30th, 2022
- Adipose derived mesenchymal stem cell secretome formulation as a biotherapeutic to inhibit growth of drug resistant triple negative breast cancer |... - December 8th, 2021
- All at-risk TN-bound travellers test Covid negative - The New Indian Express - December 8th, 2021
- Good Stocks To Invest In Right Now? 4 Health Care Stocks To Check Out - FW Business - December 8th, 2021
- Pandemic lockdown declined emotional well-being for adults with hearing, vision loss: Study - ETHealthworld.com - December 8th, 2021
- Impact of microbial contamination of haematopoietic stem cells on post-transplant outcomes: A retrospective study from tertiary care centre in India -... - August 17th, 2021
- Longeveron: Time to Buy the Di - GuruFocus.com - August 17th, 2021
- The latest on the Covid-19 pandemic in the US: Live updates - CNN - August 17th, 2021
- How this Holocaust refugee beat Covid-19 against all odds J. - The Jewish News of Northern California - August 17th, 2021
- Trade-offs among transport, support, and storage in xylem from shrubs in a semiarid chaparral environment tested with structural equation modeling -... - August 17th, 2021
- Oklahoma 10-year-old in remission after being diagnosed with rare form of leukemia 2 years ago - KFOR Oklahoma City - July 21st, 2021
- Covid: There's a serious problem with how we are testing people for the virus Neale Hanvey MP - The Scotsman - July 21st, 2021
- Profilin 1 Protein and Its Implications for Cancers - Cancer Network - July 21st, 2021
- Homing Technology Delivers Therapy to Cancerous Bone - The Scientist - July 21st, 2021
- Developmental Interest in Allogeneic PlacentaDerived Cell Therapies Expands - OncLive - July 21st, 2021
- Triple negative breast cancer and non-small cell lung cancer: Clinical challenges and nano-formulation approaches - DocWire News - July 21st, 2021
- The World's First Lab-Grown Foie Gras Could Solve This Major Concern - Mashed - July 21st, 2021
- KEYTRUDA (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Showed Statistically Significant Event-Free... - July 21st, 2021
- Human Mesenchymal Stem Cells (hMSC) Market Size 2021 | Global Trends, Business Overview, Challenges, Opportunities and Forecast to 2027 The Bisouv... - March 3rd, 2021
- [Full text] An Update on the Molecular Pathology of Metaplastic Breast Cancer | BCTT - Dove Medical Press - March 3rd, 2021
- 4D Pharma Appointments Paul Maier to the Board as Non-Executive Director - Business Wire - March 3rd, 2021
- Investigative Interventions Gain Ground in GVHD - OncLive - March 3rd, 2021
- Combination Regimens for Multiple Myeloma Show Efficacy in the Transplant-Ineligible Population, According to Dingli - Targeted Oncology - March 3rd, 2021
- Martin Makes Sense of the Rapidly Evolving MCL Treatment Paradigm - OncLive - March 3rd, 2021
- Hoth Therapeutics Expands License Agreement to Include Innovative Cancer and Anaphylactic Treatment - BioSpace - March 3rd, 2021
- Health Matters; Inflammation with Dr. Baumgartner [PODCAST] - WJON News - February 14th, 2021
- G1 Therapeutics gains first FDA nod with myelopreservation therapy Cosela | 2021-02-12 - BioWorld Online - February 14th, 2021
- Kris Gopalakrishnan on innovation - Fortune India - February 14th, 2021
- Change is coming, and at an ever-accelerating pace - Al Jazeera English - January 12th, 2021
- MCL Landscape Adapts to Changes After CAR T-Cell Therapy Approval - OncLive - January 9th, 2021
- 5 questions facing gene therapy in 2021 - BioPharma Dive - January 9th, 2021
- RNA molecules are masters of their own destiny - MIT News - January 9th, 2021
- Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market: Industry Analysis and Forecast (2019-2026): By indication type, treatment type,... - January 9th, 2021
- Harpoon Therapeutics : Clin Cancer Res 2021; OnlineFirst version Jan 6, 2021 - Marketscreener.com - January 9th, 2021
- Synthetic lethality across normal tissues is strongly associated with cancer risk, onset, and tumor suppressor specificity - Science Advances - January 5th, 2021
- Versiti Blood Centers and Noodles & Company Serve Up Thanks to Blood Donors - PRNewswire - January 5th, 2021
- January 2021: 2020 Papers of the Year - Environmental Factor Newsletter - January 5th, 2021
- Ozone in the air is bad for birds - Massive Science - January 5th, 2021
- How good are the COVID-19 vaccines? - Massive Science - January 5th, 2021
- Stem cells from cord blood can now be used across many conditions: Mayur Abhaya, MD & CEO, LifeCell Internat.. - ETHealthworld.com - December 28th, 2020
- Allogeneic SCT Benefits Children and Adolescents With Relapsed Anaplastic Large Cell Lymphoma - OncLive - December 28th, 2020
- CalvinAyre.com's most read life stories of 2020 - CalvinAyre.com - December 28th, 2020
- Coronavirus | Over 6,000 travellers from U.K. traced across States - The Hindu - December 28th, 2020
- Exosomes act as messengers and decoys to save healthy cells from viral infection - Massive Science - December 28th, 2020
- Celtics adjust to two-game series designed to reduce team travel - The Boston Globe - December 28th, 2020
- Experts Reflect on Most Impactful FDA Moves of 2020 in Solid Tumors, Hematologic Malignancies - Targeted Oncology - December 28th, 2020
- FDA Resumes eIND Approval for Severe-to-Critical COVID-19 Patients Use of Vyrologix (leronlimab) Following Full Enrollment in CytoDyn's Phase 3 Trial... - December 28th, 2020
- Magenta Therapeutics Announces Commencement of First Phase 2 Clinical Trial of MGTA-145 for Stem Cell Mobilization, Oral Presentation of MGTA-145... - December 12th, 2020
- Daratumumab Regimen Shows Promise in Transplant-Eligible Patients With Newly Diagnosed Myeloma - Targeted Oncology - December 12th, 2020
- HSCT Found Potentially Curative for Some T-Cell Lymphoma Patients - Cancer Therapy Advisor - December 12th, 2020
- Researchers Trace the Origin of Blood Cancer to Early Childhood, Decades before Diagnosis - Yahoo Finance - December 12th, 2020
- ALLO-715, Off-the-Shelf CAR T-Cell Therapy, Produces Early Promise in Multiple Myeloma - Cancer Network - December 12th, 2020
- BeiGene Announces the Approval in China of BLINCYTO (Blinatumomab) for Injection for Adult Patients with Relapsed or Refractory B-Cell Precursor Acute... - December 12th, 2020
- Flintshire youngster goes the extra mile to raise funds for Lymphoma Action | The Leader - LeaderLive - December 12th, 2020
- Meat-Tech Agrees to Acquire Cultured Fat Pioneer 'Peace of Meat' - PRNewswire - December 12th, 2020
- Stem Cell Manufacturing Market Size, Overview with Detailed Analysis, Competitive landscape, Forecast to 2027 - Cheshire Media - December 12th, 2020
- Rocket Pharmaceuticals Presents Positive Clinical Data from its Fanconi Anemia and Leukocyte Adhesion Deficiency-I Programs at the 62nd American... - December 12th, 2020